U.K. firm inches closer to isotope production, secures $323K
Tokamak Solutions has received more than $323,000 in contracts and investments toward the development of a super compact tokamak, a fusion neutron source, in part for the production of medical isotopes for the diagnosis and treatment of cancers.
Substantial fusion energy research is underway around the world, though typically in relatively large facilities. Founded in 2009 and based in Culham, England, Tokamak aims at generating a similarly powerful source of fusion energy but under a more compact design, the company said. Expected applications of the technology could include medical isotope production, nuclear waste cleanup and a potentially long-term zero carbon method for large scale hydrogen production.
Investors from the Rainbow Seed Fund, Oxford Instruments, Oxford Early Investments network and Sir Martin and Lady Audrey Wood have contributed 170,000 GBP ($273,122 USD), on top of a recent contract with the international fusion energy ITER Organization, worth EUR 110,000 ($150,000 USD).
Substantial fusion energy research is underway around the world, though typically in relatively large facilities. Founded in 2009 and based in Culham, England, Tokamak aims at generating a similarly powerful source of fusion energy but under a more compact design, the company said. Expected applications of the technology could include medical isotope production, nuclear waste cleanup and a potentially long-term zero carbon method for large scale hydrogen production.
Investors from the Rainbow Seed Fund, Oxford Instruments, Oxford Early Investments network and Sir Martin and Lady Audrey Wood have contributed 170,000 GBP ($273,122 USD), on top of a recent contract with the international fusion energy ITER Organization, worth EUR 110,000 ($150,000 USD).